TY  - GEN
AU  - Huang,Chu-Ying
AU  - Wang,Li
AU  - Feng,Cheng-Jun
AU  - Yu,Ping
AU  - Cai,Xiao-Hong
AU  - Yao,Wen-Xiu
AU  - Xu,Yong
AU  - Liu,Xiao-Ke
AU  - Zhu,Wen-Jiang
AU  - Wang,Yan
AU  - Zhou,Jin
AU  - Lu,You
AU  - Wang,Yong-Sheng
TI  - Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
SN  - 1949-2553
PY  - 2018///0209
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Crown Ethers
KW  - administration & dosage
KW  - Diphosphonates
KW  - Disease-Free Survival
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Gefitinib
KW  - Humans
KW  - Imidazoles
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Pamidronate
KW  - Protein Kinase Inhibitors
KW  - Quinazolines
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - Zoledronic Acid
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.18632/oncotarget.5515
ER  -